February 1, 1999Catheterization and Cardiovascular Interventions
A randomized comparison of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, versus aspirin in prevention of angiographic restenosis after coronary artery Palmaz-Schatz stent implantation
Why the study?
Does trapidil reduce angiographic in-stent restenosis compared to aspirin in patients undergoing Palmaz-Schatz stent implantation?
Population
118 patients undergoing Palmaz-Schatz stent implantation
Comparison
Trapidil 400 mg/d in combination with… vs Aspirin 325 mg/d in combination with ticlopidine…
Design
RCT, randomly assigned
Follow-up
6 months
Authors
Discussion
Loading...
Member takes
Implication
Trapidil shows no restenosis benefit over aspirin after stenting; reinforces aspirin as reference therapy and leaves alternatives for further testing.
Structured PICO
Does trapidil reduce angiographic in-stent restenosis compared to aspirin in patients undergoing Palmaz-Schatz stent implantation?
P
Population
118 patients undergoing Palmaz-Schatz stent implantation
I
Intervention
Trapidil 400 mg/d in combination with ticlopidine 500 mg for the first month
C
Comparator
Aspirin 325 mg/d in combination with ticlopidine 500 mg for the first month
O
Outcome
Angiographic in-stent restenosis (>50% restenosis) at 6-month angiographic follow-upsurrogate
Trapidil showed similar efficacy and safety to aspirin in preventing angiographic restenosis after coronary stenting, suggesting it could be a valuable alternative.
Cite This Study
Galassi et al. (1999) studied this question.